Research Project

Project Title:	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVECONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Project Type:	Clinical Trial, Enrolment terminated
Disease group(s):	Hereditary glomerulopathies
Project Summary:	To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS). To assess the safety and tolerability of sparsentan by double-blind monitoring of safety endpoints.
Lead principal investigator(s):	Loreto Gesualdo, Bari
Co-investigator(s):	L Ricciato, Bari V Pavone, Bari
Project Period:	12/2019 - 02/2026
Sponsors:	Industry
ClinicalTrials.gov:	NCT03493685